Merck & Co. Inc. (MRK) Financial News - Merck Receives Subpoena Related to Selling Three Medicines
Merck & Co. Inc. (MRK)
Merck Receives Subpoena Related to Selling Three Medicines
2011-08-09 04:23:31Quote: department asked for details of the marketing and selling of Temodar, PegIntron and Intron A, from January 1, 2004 to the present â€œin a federal health-care investigation,â€ Merck said today in a filing. â€œThis is the first disclosure of this matter,â€ Ronald Rogers, a spokesman for Whitehouse Station, New Jersey-based Merck, said in an e-mail. The drugmaker is cooperating with the investigation, Rogers said, declining to provide additional information. brain cancer, accounted for $1.07 billion in sales last year. Intron A for cancer and PegIntron for hepatitis C together generated $946 million in sales. New York Stock Exchange composite trading, the lowest price since August 2009. The shares have declined 17 percent this year. Pfizer Inc. is the biggest U.S. drugmaker. email@example.com. firstname.lastname@example.org ...
Open whole article (external link)
Other Financial and Stock Market News concerning Merck & Co. Inc.
Merck and Serum Institute Announce Collaboration to Develop and Expand Global Access to Pneumococcal Conjugate Vaccine (PCV) (2011-08-03 08:11:17)
Merck and Pfizer: Yielding 4% With Better Growth Prospects Than Utility Stocks (2011-08-01 05:55:40)
R&B Legend Natalie Cole Joins Rock Legend Gregg Allman, Merck and The American Liver Foundation to Turn Up The Volume Around Hep C (2011-07-26 08:29:30)
Merckâ€™s ISENTRESSÂ® (raltegravir) in Combination Therapy Demonstrated Efficacy in a Phase II Study Extending to Nearly Five Years in Previously Untreated Adults with HIV-1 (2011-07-19 06:24:53)
VICTRELISâ„¢ (boceprevir), First-in-Class Oral Hepatitis C Virus Protease Inhibitor, Approved in the European Union for Treatment of Chronic Hepatitis C (2011-07-19 06:24:52)